Alentis Therapeutics is A clinical-stage oncology company developing biologics and ADCs for claudin 1 positive tumors.

Claudin-1 (CLDN1) is a novel cancer target that is upregulated and presents a uniquely targetable epitope in many epithelial cancers, making it a potentially ideal cancer target with low potential for on-target/off-tumor toxicity. Alentis has two clinic-ready CLDN1 ADCs bearing differing cytotoxic payloads, allowing them to capture the full range of CLDN1(+) tumors which includes but is not limited to colorectal cancer, head and neck cancer, lung cancer, and endometrial cancer.

‍